Value through Innovation27 July 2016

Clinical Study Results

  • YENTREVE ® - Healthy
    Clinical Study Number 352.2058
    Study Indication Healthy
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase I
    Study Title

    Proof-of-Concept trial in healthy male and female volunteers on predictive validity of human evoked pain models in different skin conditions to test for analgesic properties of different compound classes

    Study Document Trial synopsis 352.2058 english
  • YENTREVE ® - Depressive Disorder, Major
    Clinical Study Number 1208.24
    Study Indication Depressive Disorder, Major
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IV
    Study Title

    An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression.

    Study Document Trial synopsis 1208.24_DR english
  • YENTREVE ® - Diabetic Neuropathies
    Clinical Study Number 1208.34
    Study Indication Diabetic Neuropathies
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IV
    Study Title

    A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropathic pain with and without co-morbid major depressive disorder

    Study Document Trial synopsis1208.34 english
  • YENTREVE ® - Healthy
    Clinical Study Number 1208.1
    Study Indication Healthy
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase I
    Study Title

    Tolerability and safety of 40 mg and 100 mg duloxetine BID given over 7 days in healthy female subjects. A randomised, placebo-controlled double-blind trial

    Study Document Trial synopsis 1208.1_CO english
  • YENTREVE ® - Depressive Disorder, Major
    Clinical Study Number 1208.10
    Study Indication Depressive Disorder, Major
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IIIb
    Study Title

    A ten-week, randomized, double-blind study evaluating the efficacy of duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)

    Study Document Trial synopsis 1208.10 english
  • YENTREVE ® - Pain
    Clinical Study Number 1208.31
    Study Indication Pain
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IV
    Study Title

    Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients

    Study Document Trial synopsis 1208.31 english
  • YENTREVE ® - Urinary Incontinence, Stress
    Clinical Study Number 1208.22
    Study Indication Urinary Incontinence, Stress
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IV
    Study Title

    Duloxetine Versus Placebo in the Treatment of Community-Dwelling Women Aged65 Years or Older with Stress or Stress-Predominant Mixed Urinary Incontinence

    Study Document Trial synopsis 1208.22 english
  • YENTREVE ® - Urinary Incontinence
    Clinical Study Number 1208.15
    Study Indication Urinary Incontinence
    Product YENTREVE ®
    Generic Name Duloxetine
    Lab Code
    Clinical Phase IIIa
    Study Title

    A double-blind, stratified, randomised, parallel, placebo-controlled, multicentre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence

    Study Document Trial statement 1208.15 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.